In recent years serotonin (5-hydroxytryptamine) has aroused considerable interest among radiobiologists because of its effectiveness in radioprotection, an effect discovered concurrently by Gray et al. (1) and Bacq et al. (2) in rats and mice. Subsequent investigations showed that serotonin also protected in other systems (3). Its dose-reduction factor was found to be larger than that of the known SH agents. Several hypotheses have been proposed to explain the radioprotective mechanism of serotonin. Since serotonin demonstrates pronounced pharmacological properties, its radioprotective action in vivo was thought to involve vasoconstriction and, consequently, tissue hypoxia (1, 4-8). Free radical scavenging (9) and interference with biochemical reactions (10, 11) were discussed as other possibilities. All the hypotheses suggested, however, have been questioned, and none seems to give an unambiguous explanation for the effects observed. Recently, Dukor (3) was able to show that serotonin protection cannot be attributed to hypoxia or free radical scavenging. He proposed instead that complex formation between the radiosensitive target and the protector molecule might be responsible for the observed protection. Because of the importance of serotonin in radiobiology, it is obviously of interest to investigate its mode of action, particularly if such studies lead to the discovery of substances having greater radioprotective abilities but with less pharmacodynamic side effects. Since a number of enzymes have metal ions as part of their active site, one useful line of inquiry is the investigation of complex formation between